New Drug Shows Promise for Treating Adult ADHD
An investigational drug called ALKS 7290 improved ADHD symptoms in adults during a small Phase 1B clinical trial.
Updated on Oct. 21, 2026 in Substance Abuse
Live Poll
Would you prefer a non-stimulant medication to manage your ADHD symptoms if clinically proven effective?
A recent Phase 1B study involving 138 participants suggests that the investigational drug ALKS 7290 may reduce ADHD symptoms in adults. Patients receiving the treatment showed measurable improvements in symptom scores after just six days.
Why it matters
The drug works by activating orexin type 2 receptors to modulate brain pathways linked to alertness, vigilance, and impulse control. This approach offers a potential new mechanism for managing ADHD, which often requires traditional stimulant-based therapies.
In a study of 50 adults with ADHD, the 50 mg dose of ALKS 7290 reduced median AISRS scores by 19 points and CGI-S scores by two points over 14 days. Researchers reported side effects including insomnia, dizziness, and constipation.
The players
Takeda Pharmaceuticals
This global pharmaceutical company is the manufacturer responsible for the narcolepsy drug Orzeyful.
The details
The two-week double-blind, parallel-group trial observed significant symptom declines as early as day six. The drug operates by binding to and activating specific brain receptors to lower impulsivity while enhancing sustained attention.
Timeline
August 2026 saw the FDA approve the narcolepsy medication Orzeyful.
November 2026 is when Takeda Pharmaceuticals expects Orzeyful to be available.
2027 is when results from a Phase 2 trial of ALKS 7290 are expected.
The Big Picture
This study follows the precedent of the ORION-10 statin trial by providing critical Phase 1B data to establish early efficacy benchmarks. These findings represent a fundamental step in validating a new neurological mechanism before proceeding to larger-scale validation.
For adults currently managing ADHD, this experimental drug offers a potential alternative to existing stimulants, though its current side effect profile includes insomnia and dizziness. Patients should continue working with their healthcare providers regarding approved treatment options while awaiting future clinical updates.
The takeaway
Advancements in orexin receptor targeting may provide new options for those who struggle with current ADHD medications. Patients should monitor clinical trial progress and consult with medical professionals to stay informed about potential future treatment pathways.
What happens next
Results from a Phase 2 trial of ALKS 7290 in adults with ADHD are expected in 2027.
Further reading
Find more research on treatment trends in the Substance Abuse section.
Source note: This article includes information reported by ADDitude.
Live Poll
Would you prefer a non-stimulant medication to manage your ADHD symptoms if clinically proven effective?
